Sayre Therapeutics offers clinicians a plerixafor formulation proven to be an effective hematopoietic stem cell mobilizer
- Indication: CelstemX ™ is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with Non- Hodgkin’s lymphoma and multiple myeloma
- Formulation: Plerixafor Injection for subcutaneous administration
- CelstemX ™ is
o An offering for centres that conduct bone marrow transplantations (BMTs) and can be used by a hematologist and/or medical oncologist at the centres
o Proven to offer better success rate in mobilizing stem cells (used in combination with G-CSF) and improved suitability of patients for transplantation
- In autologous transplantation cases, patients who failed to yield adequate CD34+ cells (stem cells ) or when patient is considered to be a poor mobilizer, plerixafor along with G-CSF is proven to increase the stem cell harvesting in patients, resulting in more patients proceeding to transplantation.